Roche has agreed to acquire Flatiron Health for $1.9 billion, a deal that brings the cancer research capabilities of Flatiron to the oncology drug portfolio and pipeline of the pharmaceutical giant.
Roche already owns a 12.6 percent stake in Flatiron. The Basel, Switzerland company expects to complete the acquisition of the remaining Flatiron shares in the first half of this year.
Flatiron, based in New York, makes cancer-specific electronic health record software. The data that the Flatiron software collects-stripped of patient-identifying information-is sold to drug companies and others to use in research, as well as for fine-tuning clinical trial recruitment. Flatiron… Read more »
UNDERWRITERS AND PARTNERS